Newsweek Calls Cancer Commons the “LinkedIn for Cancer” in New Feature

Newsweek’s Aimee Swartz writes about how Cancer Commons aims to change the treatment landscape in a new feature article. From the piece:

But what about those patients who’ve had an exceptional response outside a clinical trial? After all, only about 3 percent of the 1.7 million people diagnosed with cancer each year in the U.S. take part in one. “Surely there are other super responders, but unless these cases are published in medical journals or shared at medical meetings, we just are not hearing about them,” Carbone says. It is not uncommon for research data to be published years after being generated.

This is where Tenenbaum re-enters the picture. He drew on his experience as a super responder to start Cancer Commons. The nonprofit organization, based in Palo Alto, California, aims to place data relating to exceptional responders in a free, searchable online database. “If there was another patient who had similar mutations as me and who had a miraculous response to a drug, I’d want to know before I made any decisions about my treatment. Wouldn’t you?” he says.

Check out the full article at Newsweek.